Phospho-FADD (S194) Antibody

What is the biological significance of FADD phosphorylation at serine 194?

FADD phosphorylation at serine 194 significantly alters its biological function beyond the classical role in apoptosis. When phosphorylated at S194, FADD predominantly localizes to the nucleus rather than the cytoplasm, affecting several cellular processes. Research indicates that phosphorylated FADD (p-FADD) induces NF-κB activation, influences cell cycle progression, and correlates with increased cell proliferation . Notably, studies using FADD mutants (S194, A194, D194) have demonstrated that phosphorylation at this specific site is critical for nuclear localization and subsequent cellular functions. The phosphorylation status affects FADD protein stability and is associated with significantly altered biological outcomes in various cancer types .

How does phosphorylated FADD differ functionally from non-phosphorylated FADD?

Non-phosphorylated FADD primarily mediates death receptor-initiated apoptosis in the cytoplasm, while phosphorylated FADD exhibits distinct functions related to cell proliferation and survival:

• Subcellular localization: p-FADD predominantly localizes to the nucleus, while non-phosphorylated FADD is distributed throughout the cytoplasm

• Cell death signaling: Interestingly, both forms maintain comparable apoptotic signaling capacity through death receptors. Research using FADD mutants (A194, S194, D194) showed no significant difference in death potential, suggesting phosphorylation may not be critical for apoptosis induction

• NF-κB activation: p-FADD significantly activates NF-κB signaling (>2-fold compared to non-phosphorylated forms), a pathway associated with cell survival and proliferation

• Cell cycle regulation: p-FADD correlates with elevated levels of cyclin D1 and B1, promoting cell cycle progression and proliferation

• Protein stability: Phosphorylated FADD demonstrates greater protein stability compared to non-phosphorylated forms

Which kinases and phosphatases regulate FADD phosphorylation at S194?

FADD phosphorylation is regulated through a sophisticated balance of kinases and phosphatases:

Kinases promoting FADD phosphorylation:

• HIPK3 (Homeodomain-interacting protein kinase 3): Significantly reduced in T-cell lymphoblastic lymphoma; pharmacological inhibition of JNK activity leads to decreased HIPK3 expression and subsequent reduction in FADD phosphorylation

• CK1α (Casein kinase 1 alpha): Experimental inhibition using CKI-7 produces dose-dependent reduction of S194/S191-P-FADD in multiple cell lines

Phosphatases regulating FADD dephosphorylation:

• DUSP26 (Dual specificity phosphatase 26): Significantly increased in T-cell lymphoblastic lymphoma samples; pharmacological inhibition with NSC-87877 increases FADD phosphorylation levels

Experimental manipulation of these regulators using specific inhibitors produces predictable changes in FADD phosphorylation, confirming their roles in this regulatory network.

What is the relationship between p-FADD and clinical outcomes in different cancer types?

Studies across multiple cancer types reveal critical associations between p-FADD expression and clinical outcomes:

Lung Adenocarcinoma:

• Higher levels of p-FADD significantly correlate with reduced patient survival (p=0.003)

• p-FADD is predominantly localized to the nucleus in lung tumor tissues

• Tumors with higher p-FADD showed significantly elevated levels of active NF-κB and increased cyclin D1 and B1 expression

• Increased p-FADD correlates with higher cell proliferation (assessed by Ki-67 expression)

T-cell Lymphoblastic Lymphoma:

These findings indicate that p-FADD may serve as a valuable prognostic biomarker, though its expression pattern differs between cancer types, suggesting tissue-specific regulatory mechanisms.

How does p-FADD mechanistically influence NF-κB activation and cell cycle progression?

The mechanistic relationship between p-FADD, NF-κB activation, and cell cycle progression involves several interconnected pathways:

NF-κB Activation:

• Tissues with elevated levels of p-FADD show significantly higher NF-κB activation compared to those with low p-FADD (p=0.004)

• Experiments with FADD mutants demonstrate that phosphorylation is required for efficient NF-κB activation, with WT, D194, and S194 showing approximately 2-fold higher NF-κB activation than non-phosphorylatable A194 mutants

• p-FADD promotes phosphorylation of I-κB, liberating NF-κB for nuclear translocation and gene activation

• siRNA-mediated downregulation of FADD in lung cancer cells decreases phosphorylated I-κB levels, increases native I-κB, and reduces NF-κB activity by 43%

Cell Cycle Effects:

• p-FADD expression positively correlates with Ki-67 expression (r=0.26, p=0.04), indicating association with increased proliferation

• Non-phosphorylated FADD shows no correlation with Ki-67 expression (r=-0.02)

• FADD knockdown decreases cyclin D1 expression in lung cancer cells

• In T-cell lymphoblastic lymphoma, patients with higher levels of S194-P-FADD exhibit more proliferative tumors

These findings suggest that p-FADD functions as a molecular switch, directing cellular pathways away from apoptosis and toward proliferation through NF-κB activation and cell cycle promotion.

Why is S194 phosphorylation particularly critical compared to other potential phosphorylation sites in FADD?

The C-terminal domain of FADD contains multiple serine residues that could potentially be phosphorylated, yet S194 demonstrates unique significance:

• Specificity in functional outcomes: Mutation studies comparing S194A (non-phosphorylatable) and S194D (phosphomimetic) demonstrate that this specific residue mediates critical functions including nuclear localization, NF-κB activation, and cell cycle effects

• Evolutionary conservation: The S194 site (S191 in mouse) is conserved across species, suggesting functional importance maintained through evolutionary pressure

• Dominant phosphorylation site: Experiments with FADD mutants where all C-terminal serine residues except S194 were replaced with alanine (S194 mutant) still exhibited phosphorylation, confirming S194 as the primary phosphorylation target

• Distinct mobility pattern: Western blot analysis reveals that phosphorylation at S194 creates a characteristic mobility shift that distinguishes p-FADD from non-phosphorylated FADD, suggesting structural significance of this modification

• Clinical correlation: S194 phosphorylation status specifically correlates with clinical outcomes across multiple cancer types, while other potential phosphorylation sites have not demonstrated similar clinical significance

The unique position of S194 in the C-terminal domain likely provides the structural context necessary for mediating these specific biological functions.

What are the optimal detection methods for phosphorylated FADD in different experimental contexts?

Different experimental contexts require specific approaches for optimal p-FADD detection:

Western Blotting:

• Recommended for quantitative assessment of p-FADD levels

• Optimal protein loading: 20-30 μg of whole cell lysate

• Common treatments to enhance detection: nocodazole (1 μg/mL) or hydroxyurea (4 mM) for 20 hours

• Running conditions: Reducing conditions with Immunoblot Buffer Group 1

• Expected band size: Approximately 28 kDa

• 2D Western blotting can effectively distinguish between phosphorylated and non-phosphorylated FADD based on pI shift

Immunohistochemistry (IHC):

• Suitable for tissue sections and clinical samples

• Optimal protocol: Overnight incubation with primary anti-p-FADD antibody at 4°C

• Visualization system: ABC-peroxidase kit with 3,3′ diaminobenzidine tetrachloride as substrate

• Evaluation metrics: Nuclear staining intensity correlates with clinical outcomes and should be scored accordingly

Immunofluorescence:

• Ideal for subcellular localization studies

• Standard protocol: Fixed cells with NorthernLights™ 557-conjugated secondary antibody

• Counterstaining: DAPI for nuclear visualization

• Expected pattern: Nuclear localization of p-FADD in most cancer cell lines

Tissue Microarray Analysis:

• Optimal for large-scale clinical sample screening

• Scoring system: Intensity of p-FADD signals should be categorized (negative, weak, moderate, strong)

• Clinical correlation: Higher scores correlate with reduced patient survival in lung adenocarcinomas

How can researchers distinguish between phosphorylated and non-phosphorylated FADD in complex samples?

Distinguishing between phosphorylated and non-phosphorylated FADD requires specific methodological approaches:

• Phospho-specific antibodies: Use antibodies that specifically recognize FADD phosphorylated at S194, which are available commercially (e.g., MAB7047, A50306)

• 2D gel electrophoresis followed by Western blotting: This technique separates proteins based on both molecular weight and isoelectric point (pI), enabling clear distinction between phosphorylated and non-phosphorylated FADD:

  • Phosphorylated FADD shows a characteristic shift to more acidic pI

  • Two distinct protein spots with similar molecular mass but different pI values can be detected

  • Confirmation with phospho-specific antibodies can verify which spot represents p-FADD

• Mobility shift assays: Standard SDS-PAGE can reveal phosphorylation-induced mobility shifts:

  • Non-phosphorylatable mutant A194-FADD shows the highest gel mobility

  • Phosphomimetic mutant D194 demonstrates slower mobility comparable to p-FADD

  • Wild-type and S194 mutant show both slow and high mobility bands

• Phosphatase treatment controls: Sample treatment with lambda phosphatase before immunoblotting can confirm phosphorylation status:

  • Disappearance of the higher molecular weight band after phosphatase treatment confirms phosphorylation

  • Resistance to change after treatment suggests other post-translational modifications

• Subcellular fractionation: Nuclear and cytoplasmic fractions can be separated to exploit p-FADD's predominant nuclear localization versus non-phosphorylated FADD's cytoplasmic distribution

What experimental controls should be included when studying FADD phosphorylation?

Robust experimental design for studying FADD phosphorylation requires specific controls:

Positive Controls:

• Cell lines with known p-FADD expression:

  • HT-29 human colon adenocarcinoma and HeLa human cervical epithelial carcinoma treated with nocodazole (1 μg/mL) or hydroxyurea (4 mM) for 20 hours

  • SKLU-1 lung adenocarcinoma cell line (high p-FADD expression)

• Phosphorylation inducers:

  • Nocodazole treatment (microtubule depolymerizing agent)

  • Hydroxyurea treatment (DNA replication inhibitor)

Negative Controls:

• FADD-null cell line: Jurkat-/- cells are ideal negative controls for antibody specificity

• Non-phosphorylatable FADD mutants: A194 mutant (Ser to Ala substitution at position 194) serves as a control for phosphorylation-specific effects

• siRNA knockdown: FADD siRNA treatment in cells with high endogenous p-FADD expression

Specificity Controls:

• Phosphatase treatment: Lambda phosphatase treatment of lysates confirms phosphorylation-specific signals

• Antibody validation:

  • Pre-absorption with phosphorylated peptide versus non-phosphorylated peptide

  • Comparison of multiple antibodies against the same phospho-epitope

• Kinase/phosphatase manipulation:

  • HIPK3 inhibition (via JNK inhibitor SP600125)

  • CK1α inhibition (via CKI-7)

  • DUSP26 inhibition (via NSC-87877)

• Phosphomimetic control: D194 mutant (Ser to Asp substitution) mimics constitutively phosphorylated FADD

• NF-κB assay specificity controls:

  • Pre-incubation of nuclear lysates with:

    • Oligonucleotides containing NF-κB-binding consensus sequences (should decrease signal)

    • Oligonucleotides containing mutant sequences (should not affect signal)

Including these controls ensures data reliability and helps distinguish phosphorylation-specific effects from artifacts or secondary effects in FADD research.

What are common challenges in p-FADD detection and how can they be overcome?

Researchers frequently encounter several challenges when detecting p-FADD in experimental systems:

Low Signal Intensity:

• Challenge: p-FADD may be present at low levels, particularly in normal tissues

• Solution: Enhance detection through cell synchronization with nocodazole or hydroxyurea treatment for 20 hours before sample collection

• Alternative approach: Implement signal amplification methods such as tyramide signal amplification for IHC applications

Multiple Overlapping Protein Spots:

• Challenge: When using 2D PAGE, quantitative analysis of p-FADD can be difficult due to overlapping protein spots near the p-FADD spot (1120)

• Solution: Use specific phospho-antibodies in conjunction with 2D Western blotting to confirm spot identity

• Alternative approach: Employ immunoprecipitation with phospho-specific antibodies before analysis

Phosphorylation Lability:

• Challenge: Phosphorylation can be lost during sample preparation due to endogenous phosphatase activity

• Solution: Include phosphatase inhibitors (sodium orthovanadate, sodium fluoride, β-glycerophosphate) in all lysis and sample preparation buffers

• Alternative approach: Process samples rapidly at 4°C and avoid repeated freeze-thaw cycles

Background Signals in Immunostaining:

• Challenge: High background can obscure nuclear p-FADD staining in tissue sections

• Solution: Optimize blocking conditions (5% BSA or 10% normal serum from secondary antibody host species)

• Alternative approach: Use signal enhancers specifically designed for nuclear antigens

Cross-Reactivity with Other Phosphoproteins:

• Challenge: Antibodies may cross-react with similarly phosphorylated motifs

• Solution: Validate antibody specificity using FADD-null cell lines (e.g., Jurkat-/-) and A194 mutant controls

• Alternative approach: Confirm results with multiple antibodies recognizing different epitopes around the phosphorylation site

How can researchers effectively manipulate FADD phosphorylation status in experimental systems?

Researchers can effectively modulate FADD phosphorylation through several experimental approaches:

Genetic Manipulation:

• FADD mutant expression systems:

  • Non-phosphorylatable mutant (A194): Serine to alanine substitution at position 194

  • Phosphomimetic mutant (D194): Serine to aspartic acid substitution at position 194

  • S194 mutant: All serine residues in C-terminal domain except S194 replaced with alanine

• Expression vectors and stable cell lines:

  • FADD-null cell lines (e.g., Jurkat-/-) provide clean backgrounds for mutant expression

  • Inducible expression systems allow temporal control of FADD variant expression

Pharmacological Manipulation:

• Kinase inhibitors to reduce FADD phosphorylation:

  • JNK inhibitor SP600125: Leads to decreased HIPK3 expression and subsequent reduction in FADD phosphorylation

  • CK1α inhibitor CKI-7: Produces dose-dependent reduction of S194/S191-P-FADD

• Phosphatase inhibitors to increase FADD phosphorylation:

  • DUSP26 inhibitor NSC-87877: Increases FADD phosphorylation levels

• Cell cycle modulators:

  • Nocodazole (1 μg/mL): Microtubule depolymerizing agent that enhances FADD phosphorylation

  • Hydroxyurea (4 mM): DNA replication inhibitor that increases FADD phosphorylation

RNA Interference:

• siRNA targeting:

  • FADD siRNA: For total FADD knockdown

  • Targeted siRNAs against specific kinases (HIPK3, CK1α) or phosphatases (DUSP26) that regulate FADD phosphorylation

• shRNA for stable knockdown:

  • Establish stable cell lines with reduced expression of FADD or its regulatory kinases/phosphatases

Cell-Permeable Peptides:

• TAT-FADD conjugates: Cell-penetrable peptide-conjugated FADD can be used to introduce specific FADD variants (WT or mutants) directly into cells

Successful manipulation requires validation of phosphorylation status using Western blotting with phospho-specific antibodies and assessment of functional outcomes through NF-κB activation assays and cell cycle analysis.

What emerging research directions are advancing our understanding of FADD phosphorylation in disease progression?

Several cutting-edge research directions are expanding our understanding of FADD phosphorylation in disease contexts:

Cancer Biomarker Development:

• Integration of p-FADD detection with other prognostic markers to develop multi-parameter prognostic tools

• Exploration of p-FADD as a predictive biomarker for treatment response in various cancer types

• Investigation of tissue-specific variations in p-FADD significance, as evidenced by contrasting patterns in lung adenocarcinoma versus T-cell lymphoblastic lymphoma

Therapeutic Targeting Strategies:

• Development of small molecule inhibitors specifically targeting FADD phosphorylation

• Exploration of cell-penetrable peptide-conjugated FADD (TAT-FADD) as a therapeutic approach for cancer treatment

• Investigation of combination therapies targeting both p-FADD and NF-κB pathways to overcome resistance mechanisms

Regulatory Network Mapping:

• Comprehensive mapping of the upstream regulatory network controlling FADD phosphorylation in different cell types

• Investigation of additional phosphorylation sites beyond S194 and their potential synergistic effects

• Exploration of epigenetic mechanisms regulating FADD expression and phosphorylation through cis-regulatory elements

Novel Detection Technologies:

• Development of high-sensitivity single-cell approaches to detect p-FADD in rare cell populations

• Application of proximity ligation assays to visualize interactions between p-FADD and downstream effectors

• Integration of proteomics approaches to identify novel p-FADD interacting partners in the nucleus

Mechanistic Understanding:

• Investigation of p-FADD's role in nuclear processes including chromatin remodeling and transcriptional regulation

• Exploration of the relationship between p-FADD and immune evasion mechanisms in cancer

• Examination of p-FADD's influence on therapy resistance pathways in various cancer types

These emerging directions hold promise for translating basic research findings into clinical applications, potentially positioning p-FADD as both a prognostic biomarker and therapeutic target for cancer and other diseases.